Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.58 |
| ▸ | LPL | P06858 | 11/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | P4HB | P07237 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23624415 | 0.99 | LIPG (0.55) | LIPGLPLESR2DGAT1P4HB | |
| SCHEMBL22652888 | 0.88 | LIPG (0.62) | LIPGLPLESR2CYP11B2KIF11 | |
| SCHEMBL15496904 | 0.88 | LIPG (0.62) | LIPGLPLESR2CYP11B2KIF11 | |
| SCHEMBL15301292 | 0.88 | LIPG (0.62) | LIPGLPLESR2CYP11B2KIF11 | |
| SCHEMBL22064786 | 0.88 | LPL (0.42) | LIPGLPLPDK2CYP11B2TNKS | |
| SCHEMBL23635769 | 0.87 | LIPG (0.55) | LIPGLPLESR2DGAT1P4HB | |
| SCHEMBL21416068 | 0.86 | LIPG (0.54) | LIPGLPLESR2DGAT1P4HB | |
| SCHEMBL30233361 | 0.86 | LPL (0.40) | LIPGLPLPDK2CYP11B2TNKS | |
| SCHEMBL21878519 | 0.86 | LPL (0.40) | LIPGLPLPDK2CYP11B2TNKS | |
| SCHEMBL20713464 | 0.85 | LIPG (0.47) | LIPGLPLESR2CYP11B2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11588111-B2 | Condensed-cyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-02-21 | — | — | US | disclosed |
| WO-2020226280-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | 주식회사 엘지화학 | 2020-11-12 | — | — | WO | disclosed |
| US-20190044072-A1 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11588111-B2 | Condensed-cyclic compound and organic light-emitting device including the same | CRY1, CRY2, CCNE2 | LIPG 2966/4885LPL 2183/4885ESR2 326/4885 |
| US-20190044072-A1 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNE2 | LIPG 2966/4885LPL 2183/4885ESR2 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.